Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden

Show simple item record Hemminki, Kari Försti, Asta Hemminki, Akseli Ljungberg, Börje Hemminki, Otto 2021-09-20T10:00:01Z 2021-09-20T10:00:01Z 2021-06-22
dc.identifier.citation Hemminki , K , Försti , A , Hemminki , A , Ljungberg , B & Hemminki , O 2021 , ' Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden ' , PLoS One , vol. 16 , no. 6 , 0253236 .
dc.identifier.other PURE: 168610856
dc.identifier.other PURE UUID: 47124ddf-c72a-44fc-b3f9-390a7afc70da
dc.identifier.other WOS: 000671691200015
dc.description.abstract Global survival studies have shown favorable development in renal cell carcinoma (RCC) treatment but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed RCC survival in Finland and Sweden over a 50-year period (1967-2016) using data from the NORDCAN database provided by the local cancer registries. While the health care systems are largely similar in the two countries, the economic resources have been stronger in Sweden. In addition to the standard 1- and 5-year relative survival rates, we calculated the difference between these as a measure of how well survival was maintained between years 1 and 5. Relative 1- year survival rates increased almost linearly in both countries and reached 90% in Sweden and 80% in Finland. Although 5-year survival also developed favorably the difference between 1- and 5-year survival rates did not improve in Sweden suggesting that the gains in 5-year survival were entirely due to gains in 1-year survival. In Finland there was a gain in survival between years 1 and 5, but the gain in 1-years survival was the main contributor to the favorable 5-year survival. Age group specific analysis showed large survival differences, particularly among women. Towards the end of the follow-up period the differences narrowed but the disadvantage of the old patients remained in 5-year survival. The limitations of the study were lack of information on performed treatment and clinical stage in the NORDCAN database. In conclusion, the available data suggest that earlier diagnosis and surgical treatment of RCC have been the main driver of the favorable change in survival during the past 50 years. The main challenges are to reduce the age-specific survival gaps, particularly among women, and push survival gains past year 1. en
dc.format.extent 10
dc.language.iso eng
dc.relation.ispartof PLoS One
dc.rights cc_by
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject CANCER
dc.subject IMPACT
dc.subject DIAGNOSTICS
dc.subject PREDICTION
dc.subject TRENDS
dc.subject END
dc.subject 3122 Cancers
dc.title Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden en
dc.type Article
dc.contributor.organization Department of Oncology
dc.contributor.organization HUS Comprehensive Cancer Center
dc.contributor.organization TRIMM - Translational Immunology Research Program
dc.contributor.organization Clinicum
dc.contributor.organization Research Programs Unit
dc.contributor.organization University of Helsinki
dc.contributor.organization HUS Abdominal Center
dc.contributor.organization Urologian yksikkö
dc.description.reviewstatus Peer reviewed
dc.relation.issn 1932-6203
dc.rights.accesslevel openAccess
dc.type.version publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
journal.pone.0253236.pdf 1.075Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record